By targeting underlying synovitis, the novel intra-articular liraglutide formulation 4P004 aims to bridge the gap between transient symptom relief and disease modification in knee OA.
The FDA review of the biologics license application includes data on SC isatuximab as both manual injection and via an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results